Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
ConditionProlactinoma
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral glucose tolerance test.
Eligibility criteria
Qualifiers
Diagnosed adult patients (at least 18 years of age) with prolactinoma-induced hyperprolactinemia, defined as a prolactin level ≥ two times the local laboratory maximum and radiographic criteria, based on current guidelines.
Diagnosed adult patients (at least 18 years of age) with prolactinoma-induced hyperprolactinaemia based on current guidelines.
Patients treated with cabergoline as DA therapy and prolactin levels within the normal range
Disqualifiers
alternative explanation for hyperprolactinaemia
Active substance use disorder within the last six months
Current or previous psychotic disorder
Pregnancy or breastfeeding within the last 8 weeks
Trial design
Treatments tested in this trial
- Cabergoline (Dopamine Agonist)
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov